DUBLIN–(BUSINESS WIRE)–The “Spinal Cord Injury – Pipeline Insight, 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This “Spinal Cord Injury – Pipeline Insight, 2020,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Spinal Cord Injury pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Treatment
Treatments for Spinal Cord Injury includes surgery, medication and physical therapy. The primary aid or measures should be taken immediately to minimize the injury. Corticosteroid injections may help in spinal cord injuries. Research is going on to find new treatment therapy including prostheses and medications that may promote nerve cell regeneration or improve the function of the nerves after a spinal cord injury. Neural prostheses (artificial body parts) are a potential new treatment for spinal cord injuries. Regular rehabilitation and assistive devices can improve the quality of life.
Spinal Cord Injury Emerging Drugs Chapters
This segment of the Spinal Cord Injury report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Spinal Cord Injury Emerging Drugs
- Hepatocyte growth factor – Kringle Pharma
Hepatocyte growth factor (KP-100IT) is a recombinant human HGF (rhHGF). It is under Phase III clinical development for acute spinal cord injury and amyotrophic lateral sclerosis (ALS). Hepatocyte growth factor (HGF) is considered as an intrinsic repair and regeneration factor for various tissues and organs. The therapy has been received an orphan drug designation by the Ministry of Health, Labor and Welfare as of September 12, 2019.
- ES135: Eusol Biotech
ES135 is a recombinant human acidic fibroblast growth factor (rhFGF1) with 135 amino acids. ES135 promote neurite outgrowth. The sequence of ES135 has been patented in Taiwan, EU, China and the United States. ES135 is undergoing a multi-center, double blind, randomized, placebo control study as the pivotal Phase 3 clinical trial for spinal cord injury.
Spinal Cord Injury: Therapeutic Assessment
This segment of the report provides insights about the different Spinal Cord Injury drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Spinal Cord Injury
There are approx. 40+ key companies which are developing the therapies for Spinal Cord Injury. The companies which have their Spinal Cord Injury drug candidates in the most advanced stage, i.e. phase III include, Kringle Pharma.
Phases
This report covers around 40+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Spinal Cord Injury pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Spinal Cord Injury: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Spinal Cord Injury therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spinal Cord Injury drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Spinal Cord Injury R&D. The therapies under development are focused on novel approaches to treat/improve Spinal Cord Injury.
- In October 2019, GTX Medical and NeuroRecovery Technologies announced their merger to create a leading global company committed to developing novel neuromodulation therapies to improve functional recovery of people with Spinal Cord Injuries (SCI). The merged entity will be known as GTX Medical BV. The merged company is developing Targeted Epidural Spine Stimulation (TESS), an implantable spinal cord stimulation system with real-time motion feedback.
Spinal Cord Injury Report Insights
- Spinal Cord Injury Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Spinal Cord Injury Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Spinal Cord Injury drugs?
- How many Spinal Cord Injury drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Spinal Cord Injury?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Spinal Cord Injury therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Spinal Cord Injury and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Kringle Pharma
- Eusol Biotech
- Pharmicell
- Pharmazz
- AbbVie
- Acorda Therapeutics
- Geron Corporation
- ReNetX Bio
- GNT Pharma
- AlaMab Therapeutics
- Mitsubishi Tanabe Pharma
- Kancera
- Olatec Therapeutics
- Scholar Rock
- AXONIS Therapeutics
- K-STEMCELL
Key Products
- Hepatocyte growth factor
- ES135
- Autologous mesenchymal stem cell therapy
- Sovateltide
- Elezanumab
- Fampridine sustained release
- OPC 1
- AXER-204
- Nelonemdaz
- ALMB 0166
- MT-3921
- KAND 567
- Dapansutrile
- Apitegromab
- AAV gene therapy
- Stem cell therapies
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/lr5ba5
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900